Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin.
Clicks: 214
ID: 105223
2019
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
4.2
/100
14 views
14 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
This is the first case report of alectinib as a bridge to allo-SCT in a patient with ALK-positive ALCL refractory to both conventional chemotherapies and BV. This report offers a ray of hope for a condition with poor prognosis.
| Reference Key |
nakai2019alectinibclinical
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Nakai, Ritsuko;Fukuhara, Suguru;Maeshima, Akiko Miyagi;Kim, Sung-Won;Ito, Yuta;Hatta, Shunsuke;Suzuki, Tomotaka;Yuda, Sayako;Makita, Shinichi;Munakata, Wataru;Suzuki, Tatsuya;Maruyama, Dai;Izutsu, Koji; |
| Journal | Clinical case reports |
| Year | 2019 |
| DOI |
10.1002/ccr3.2543
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.